Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 11/20 | 0.63 |
| ▸ | MGAM | O43451 | 9/20 | 0.63 |
| ▸ | AMY1A | P0DUB6 | 9/20 | 0.63 |
| ▸ | SI | P14410 | 9/20 | 0.63 |
| ▸ | MGAM2 | Q2M2H8 | 9/20 | 0.63 |
| ▸ | RAB9A | P51151 | 7/20 | 0.63 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109729 | 0.84 | GAA (0.63) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL29625506 | 0.81 | GAA (0.73) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL361654 | 0.81 | GAA (0.73) | GAAMGAMAMY1ASIMGAM2 | |
| Hydrochloric Acid SCHEMBL1371916 | 0.80 | GAA (0.71) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL16286769 | 0.80 | GAA (0.67) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL29937880 | 0.80 | GAA (0.67) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL1689837 | 0.80 | GAA (0.67) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL2070662 | 0.80 | GAA (0.67) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL11524883 | 0.80 | GAA (0.67) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL1775885 | 0.79 | RAB9A (0.61) | GAAMGAMAMY1ASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189369-A1 | MULTI-ARM POLYMERIC ALKANOATE CONJUGATES | NEKTAR THERAPEUTICS | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189369-A1 | MULTI-ARM POLYMERIC ALKANOATE CONJUGATES | ALK, ALKBH3, PAICS | GAA 199/4885MGAM 377/4885AMY1A 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.